George Shenouda, MD, PhD

Disclosure:
No relationships to disclose.

Presentation(s):

• 96 - A Phase 2 Trial of Neoadjuvant Temozolomide (TMZ) Followed By Accelerated Hypofractionated Radiation Therapy (AHRT) and TMZ Followed By Adjuvant TMZ in Patients with Newly Diagnosed Glioblastoma (GBM): Long Term Survival and Toxicity Analysis

  Monday, October 22
  11:35 AM – 11:45 AM